First Northern Ireland director for ABPI announced
pharmafile | November 6, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, Colette Goldrick, Ireland
The ABPI has confirmed the appointment of Colette Goldrick as its new Northern Ireland director and as a member of the ABPI Senior Leadership Team.
She becomes the ABPI’s first dedicated Northern Ireland director and will begin work on 12 November.
Goldrick, who comes from Northern Ireland, has a long history of working in senior roles in the pharmaceutical industry. Her career includes eight years at Glaxo in their Public Affairs and Communications team, where she left as head of Communications.
Goldrick also spent nine years at Pfizer in various capacities – head of Communications, Corporate Affairs director and head of Public Affairs and Policy for Pfizer Europe. In her last role at Pfizer she led a team of 30, responsible for corporate reputation, policy development, government relations and communications strategy as well as overseeing the work of a significant corporate affairs team across the EU.
Goldrick will be supported in her work by Marion Laverty who will provide office management. Laverty will also help identify, establish and develop productive relationships with key opinion leaders and decision makers in Northern Ireland.
Stephen Whitehead, chief executive of the ABPI, said: “I am delighted that we have secured such a strong talent in Colette to build and lead the ABPI in Northern Ireland. The ABPI believes that Northern Ireland represents a significant opportunity for the bio-pharmaceutical industry in terms of the growing life science agenda, arising from world class capability at Queen’s University Belfast, the University of Ulster and the Science Park.
“Our partnership based approach will seek to engage all stakeholders in supporting healthcare professionals to effectively utilise innovative medicines and improve patient health. Northern Ireland has a better record of using innovative medicines and consequently in several critical areas has better patient outcomes than England, most notably in certain cancers and forms of heart disease.
“Colette will work closely with our members in Northern Ireland whilst drawing on expertise in the London office.”
Related Content
Astellas plans to invest over €330m in new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build …
The November 2020 issue of Pharmafocus is available to read free online now!
The latest monthly edition of Pharmafocus is available to read for free online now!
UK life sciences industry does not want no-deal Brexit, says ABPI Chief
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a …
